



AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application:

1-17. (Canceled)

18. (Currently Amended) An isolated complex of the Formula I or Formula II:



wherein:

m is an integer from 1-5;

n is an integer from 1-100;

o is an integer from 1-5;

p is an integer from 1-100;

AV is an antiviral compound;

L1 and L2 are polyvalent linkers covalently linking AV to Pr, or where L1 and L2 are absent;

Pr is a protein; and

wherein the complex ~~possesses antiviral activity~~ inhibits HIV *in vivo*.

19. (Original) The complex of Claim 18, wherein the antiviral compound is a peptide.

20. (Original) The complex of Claim 19 wherein the peptide has a mass of less than about 100 kDA.

21. (Original) The complex of Claim 19, wherein the peptide has a mass of less than about 30 kDA.

22. (Original) The complex of Claim 19, wherein the peptide has a mass of less than about 10 kDA.

23. (Original) The complex of Claim 19 wherein the peptide is a peptidomimetic.

24. (Currently Amended) The complex of Claim 19 wherein the peptide consists of up to 51 amino acids comprising a sequence selected from the group consisting of:

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6, SEQ ID NO: 843;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7, SEQ ID NO: 844;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8, SEQ ID NO: 844;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9, SEQ ID NO: 846;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10, SEQ ID NO: 847;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11, SEQ ID NO: 848;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12, SEQ ID NO: 849;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13, SEQ ID NO: 850;

Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 851;

Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 852;

Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 852;

Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 854;

Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 855;

Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 856;

W-X-X-W-X-X-X-I-X-X-X-T-X-X-I-X-X-L-I-X-X-X-Q-X-Q-Q-X-X-N, SEQ ID NO: 857;

W-X1-X2-W-X3-X4-X5-I-X6-X7-X8-T-X9-X10-I-X11-X12-L-I-X13-X14-X15-Q-X16-Q-Q-X17-X18-N-X19-X20-X21-X22-X23, SEQ ID NO: [[857]] 858;

peptide DP178 (T-20); and

peptide T-1249;

wherein:

Y1 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;

Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;

Y3 is selected from the group consisting of I, V, L, A, S and T;

Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;

Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and H;

Y6 is selected from the group consisting of any amino acid except P, G and C;

Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;

Y8 is selected from the group consisting of Q, H, R, N, E, D, K and P;

Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;

Y10 is selected from the group consisting of Q, H, N, E, D, K and R;

Y11 is selected from the group consisting of N, S, T, V, A and D;

Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;

Y13 is selected from the group consisting of L, I, V, K and R;

Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R;

X1 is selected from the group consisting of M, L, I, Q, T, R and K;

X2 is either E, D, Q and K;

X3 is selected from the group consisting of E, D and K;

X4 is selected from the group consisting of K, R, E, Q, N and T;

X5 is selected from the group consisting of E, L, R, K and Q;

X6 is selected from the group consisting of N, D, S, E, Q, K, R, H, T, I and G;

X7 is selected from the group consisting of N, Q, D, E, K, S, T and Y;

X8 is selected from the group consisting of Y, F, H, I, V and S;

X9 is selected from the group consisting of G, K, R, H, D, E, S, T, N and Q;
X10 is selected from the group consisting of K, H, E, Q, T, V, I, L, M, A, Y, F, and P;
X11 is selected from the group consisting of H, K, E, Y and F;
X12 is selected from the group consisting of T, S, Q, N, E, D, R, K, H, W, G, A, and M;
X13 is selected from the group consisting of D, E, Q, T, K, R, A, V and G;
X14 is selected from the group consisting of D, E, K, H, Q, N, S, I, L, V, A and G;
X15 is selected from the group consisting of S, A and (P);
X16 is selected from the group consisting of N, K, S, T, D, E, Y, I and V;
X17 is selected from the group consisting of E, D, N, K, G, and V;
X18 is selected from the group consisting of K, R, H, D, E, N, Q, T, M, I, and Y;
X19 is selected from the group consisting of E, V, Q, M, L, J, and G;
X20 is selected from the group consisting of Q, N, E, K, R, H, L, and F;
X21 is selected from the group consisting of E, D, N, S, K, A, and G;
X22 is selected from the group consisting of L, I, and Y; and
X23 is selected from the group consisting of I, L, M, Q, S, and Y.

25. (Original) The complex of Claim 24 wherein the protein is a blood component.

26. (Original) The complex of Claim 25, wherein the blood component is selected from the group consisting of red blood cells, immunoglobulins, IgM, IgG, serum albumin, transferrin, P90 and P38, ferritin, a steroid binding protein, thyroxin binding protein, and α -2-macroglobulin.

27. (Original) The complex of Claim 25, wherein the blood component is human serum albumin and the linker is a peptide linker.

28. (Original) The complex of Claim 25, wherein the blood component is human serum albumin and the linker is a non-peptide linker.

29. (Canceled)

30. (Original) The complex of Claim 18, wherein the linker L1 or L2 is a non-labile linker that is stable toward hydrolytic cleavage *in vivo*.

31-145. (Canceled)